25.06.2012 • News • Lonza • BioWa • cell culture

Lonza, Biowa Sign License Agreements with FivePrime Therapeutics

FivePrime Therapeutics has entered into research and commercial agreements with Biowa and Lonza to use their Potelligent CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of Biowa's engineered glycosylation Potellingent Technology with the advantages of Lonza's proprietary GS Gene Expression Systems, which includes the industry-leading CHOK1SV cell line.

 

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Top-Feature

most read

Photo
28.07.2025 • News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.